本文選題：間充質(zhì)干細(xì)胞 + 混合淋巴細(xì)胞反應(yīng)��； 參考：《南京醫(yī)科大學(xué)》2005年碩士論文

【摘要】：目的 探討體外無血清培養(yǎng)擴(kuò)增臨床規(guī)模人骨髓間充質(zhì)干細(xì)胞(MSCs)及其抑制淋巴細(xì)胞增殖的免疫調(diào)節(jié)特性。 方法 人骨髓MSCs來自12例正常人及惡性血液病患者,采用無血清培養(yǎng)基體外培養(yǎng)。外周血淋巴細(xì)胞來自2例正常志愿者。MSCs與單向混合淋巴細(xì)胞(MLRs)和雙向MLRs共培養(yǎng),應(yīng)用二乙酰羧基熒光素-琥珀酰亞胺酯(CFSE)標(biāo)記雙向MLRs中反應(yīng)細(xì)胞。細(xì)胞增殖應(yīng)用Cell Counting Kit-8(CCK-8)試劑盒檢測,T細(xì)胞細(xì)胞亞群采用流式細(xì)胞術(shù)(FCM)分析。 結(jié)果 能夠從所有26.3±8.8 mL骨髓樣本中提取MSCs,其中10例成功擴(kuò)增。擴(kuò)增后MSCs表面表達(dá)CD105、CD73、CD13、CD90,而不表達(dá)骨髓造血細(xì)胞的表面抗原。MSCs呈劑量依賴性非MHC限制性抑制同種抗原誘導(dǎo)的淋巴細(xì)胞增殖。Th2、Tc2比例降低,Th1、Tc1比例無明顯變化;T細(xì)胞早期活化標(biāo)記CD69表達(dá)增強;CD4+CD25+調(diào)節(jié)性T細(xì)胞(CD4+CD25+Tr)比例增加。
[Abstract]:Objective to investigate the immunomodulatory characteristics of human bone marrow mesenchymal stem cells (MSCs) in vitro in serum-free culture.Methods Human bone marrow MSCs was cultured in serum-free medium in 12 normal subjects and patients with hematologic malignancies.Peripheral blood lymphocytes from 2 normal volunteers were co-cultured with unidirectional mixed lymphocytes (MLRs) and bidirectional MLRs. The reactive cells were labeled with diacetyl carboxyl fluorescein succinimide ester (CFSE) in bidirectional MLRs.Cell Counting Kit-8 CCK-8 kit was used to detect T cell subsets by flow cytometry (FCM).Results MSCs were extracted from all 26.3 鹵8.8 mL bone marrow samples, 10 of which were successfully amplified.The surface antigen of bone marrow hematopoietic cells was not expressed on the surface of MSCs in a dose-dependent manner. MSCs inhibited the proliferation of lymphocytes induced by alloantigen in a dose-dependent manner. Th2Tc2 decreased the ratio of Th _ 1 to Tc _ 1. There was no significant change in the early survival of T cells.The expression of CD69 increased with the increase of CD4 CD25 regulatory T cell CD 4 CD25 Tr.
【學(xué)位授予單位】：南京醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2005
【分類號】：R392

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 李建勇,吳漢新,任志宏,張曉艷,黃峻,汪承亞;異基因間充質(zhì)干細(xì)胞和造血干細(xì)胞聯(lián)合移植治療難治白血病的初步臨床研究[J];江蘇醫(yī)藥;2003年10期

，

本文編號：1756187